Video Shorts

Tegoprubart's Innovative Transplant Immunosuppression

Berotralstat: First Oral HAE Prophylaxis Approved for Ages 2–11

New Data Released Highlighting Zasocitinib Results in Psoriasis

A Medical Breakthrough Decades in the Making

PREVAIL: Felzartamab in IgA nephropathy With Jurgen Floege

Lumateperone Reduces Depression Symptoms Within 1 – 2 Weeks

The Medical Sisterhood: Redefining Leadership and Mentorship in Dermatology

GLP-1s and the Heart: Wegovy's New Cardiovascular Indication

Skin of Color Savvy: Key Highlights from 2025

Multi-Food OIT Paused, But Clinics and Biologics Keep Allergy Options Expanding

New FDA-Approved HAE Drugs Target Multiple Points in the Contact System

Traveling with GLP-1s: Why a Pill Changes Everything

The Unknown Long-Term Impacts of GLP-1 Medications

New Oral GLP-1s Provide Alternatives to Injection

FDA Approves First-Of-Its-Kind Oral GLP-1 For Weight Loss

Single- to Multi-Food Immunotherapy Is a Natural Progression in Allergy Care

Diabetes Dialogue: Predicting the Glucose Impact of Meals with Libre Assist

Diabetes Dialogue: 2026 ADA Standards of Care and Insulin Pump Use

Diabetes Dialogue: Retatrutide Reduces Body Weight 28.7% in Phase 3 Trial

Dexcom G6 is Retiring: The End of an Era for CGM Users

New Phase 3 Data Support FDA-Approved Lumateperone as Add-On in MDD

Tips on Winter Skincare Routines for Patients with Skin of Color

Diabetes Dialogue: Retatrutide’s Impact on Osteoarthritis in TRIUMPH-4

QOL and Platelet Improvement With New ITP Drug

AI Blood Test Quickly Identifies MDD Patients Fit for V1b Blocker

The Move to Treatable Traits for COPD and Asthma

Insulet Announces Next-Gen Omnipod 6 Coming in 2027

Phase 3 NATRON Trial Shows Benefits of Benralizumab for HES

The Biggest Challenges Facing New Insulin Pumps

Using New Therapies to Address Triglycerides in FCS